Peritoneal Surface Malignancies: Cytoreductive Surgery, HIPEC, and Multidisciplinary Care
Peritoneal surface malignancies occur when cancer spreads to the peritoneum, the thin membrane lining the abdominal cavity and covering many abdominal organs. These tumors may arise from cancers originating within the abdomen or represent metastatic spread from gastrointestinal or gynecologic malignancies.
Historically, peritoneal metastases were considered uniformly incurable. Advances in surgical oncology over the past several decades have changed this paradigm. In carefully selected patients, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can provide meaningful long-term disease control and, in selected cases, durable remission.
Management of peritoneal surface malignancies requires specialized expertise in peritoneal tumor biology, complex abdominal surgery, and multidisciplinary cancer care.
As a fellowship-trained surgical oncologist specializing in complex gastrointestinal and hepatopancreatobiliary malignancies, Dr. Geoffrey W. Krampitz provides evaluation and surgical management of selected peritoneal surface malignancies within a coordinated multidisciplinary oncology program.
Understanding Peritoneal Surface Malignancies
The peritoneum is a large, thin membrane that lines the abdominal cavity and supports many abdominal organs. Tumor cells can spread along these surfaces through the circulation of peritoneal fluid, leading to dissemination across the abdominal cavity.
Peritoneal metastases most commonly arise from:
Appendiceal tumors and pseudomyxoma peritonei
Colorectal cancer
Gastric cancer
Small intestinal adenocarcinoma
Ovarian cancer
Unlike metastases that spread through the bloodstream to distant organs, peritoneal tumors frequently remain confined to the abdominal cavity, which is why regional treatment strategies such as CRS-HIPEC may be effective in selected patients.
For more information regarding mucinous appendiceal tumors and pseudomyxoma peritonei, see Appendiceal Tumors.
Symptoms of Peritoneal Metastases
Symptoms vary depending on the underlying tumor type and the extent of disease within the abdominal cavity.
Possible symptoms include:
abdominal bloating or increasing abdominal girth
abdominal discomfort or fullness
early satiety
changes in bowel habits
nausea or vomiting
unintentional weight loss
In mucin-producing tumors such as pseudomyxoma peritonei, progressive accumulation of mucin within the abdomen may lead to significant abdominal distention and digestive symptoms.
Diagnostic Evaluation
Evaluation focuses on determining:
the extent of peritoneal disease
the primary tumor source
whether complete cytoreduction may be achievable
Diagnostic testing typically includes:
CT scan of the chest, abdomen, and pelvis
MRI in selected cases
diagnostic laparoscopy when imaging is inconclusive
Cross-sectional imaging helps assess tumor distribution, although radiographic studies may underestimate disease burden. In selected patients, diagnostic laparoscopy provides direct visualization of the peritoneal cavity, allowing more accurate evaluation of tumor extent prior to major surgery.
Peritoneal Cancer Index (PCI)
The Peritoneal Cancer Index (PCI) is a standardized scoring system used to quantify the extent of tumor involvement throughout the abdominal cavity.
The abdomen is divided into multiple regions, and tumor burden in each region is assigned a score based on lesion size.
PCI plays an important role in determining:
surgical feasibility
likelihood of achieving complete tumor removal
overall treatment strategy
Patients with limited peritoneal disease burden are more likely to benefit from cytoreductive surgery.
Quantification of tumor burden using PCI, combined with assessment of tumor biology and response to systemic therapy, forms the foundation of modern patient selection for cytoreductive surgery.
Cytoreductive Surgery (CRS)
Cytoreductive surgery is an extensive procedure designed to remove all visible tumor deposits within the abdominal cavity.
This may involve removal of tumor from:
the peritoneal lining
portions of the intestine
the omentum
involved abdominal organs when necessary
The objective of surgery is complete macroscopic tumor removal, often described as complete cytoreduction (CC-0 or CC-1).
Because peritoneal disease frequently involves multiple abdominal surfaces, these procedures require meticulous surgical technique, careful patient selection, and experienced perioperative management.
Successful outcomes in peritoneal surface malignancy surgery are closely associated with the ability to achieve complete cytoreduction (CC-0/CC-1) within experienced programs familiar with complex multivisceral abdominal surgery.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Following cytoreductive surgery, heated chemotherapy may be circulated within the abdominal cavity.
This technique, known as hyperthermic intraperitoneal chemotherapy (HIPEC), allows chemotherapy to:
directly contact microscopic tumor cells
penetrate residual tumor deposits
achieve high local drug concentrations while limiting systemic toxicity
Heat enhances the effectiveness of certain chemotherapy agents and improves tissue penetration.
The combination of CRS and HIPEC is designed to address both visible tumor deposits and microscopic residual disease.
Tumor-Specific Treatment Strategies
Treatment strategy varies according to the primary cancer type and underlying tumor biology.
Appendiceal Tumors
Low-grade appendiceal mucinous tumors with pseudomyxoma peritonei are among the diseases most commonly treated with CRS-HIPEC, often with favorable long-term outcomes.
See Appendiceal Tumors for more information.
Colorectal Cancer
Selected patients with colorectal peritoneal metastases may benefit from cytoreductive surgery in combination with systemic therapy when disease remains confined to the abdomen.
See Colon Cancer for additional details.
Gastric Cancer
Peritoneal metastases from gastric cancer often demonstrate more aggressive tumor biology. Treatment strategies are individualized based on systemic therapy response and overall disease burden.
See Gastric Cancer for additional information.
Patient Selection
Not all patients with peritoneal metastases benefit from CRS-HIPEC.
Careful evaluation considers:
tumor biology and grade
distribution of disease within the abdomen
PCI score
response to systemic therapy
overall patient health and physiologic reserve
These complex decisions are best made within experienced multidisciplinary tumor boards specializing in peritoneal surface malignancies.
Potential Risks of Cytoreductive Surgery
CRS-HIPEC is a major surgical procedure requiring careful perioperative management.
Potential risks include:
bleeding
infection
anastomotic leak
ileus or delayed bowel function
blood clots
temporary organ dysfunction
When performed within experienced programs, careful patient selection and structured postoperative care help optimize outcomes.
Recovery and Follow-Up
Recovery following CRS-HIPEC varies depending on the extent of surgery and patient-specific factors.
Patients typically receive:
structured postoperative monitoring
nutritional support
long-term oncologic surveillance
Follow-up plans are individualized according to tumor biology and treatment response.
Multidisciplinary Peritoneal Surface Malignancy Care
Management of peritoneal surface malignancies requires collaboration among multiple specialists, including:
surgical oncology
medical oncology
gastroenterology
radiology and pathology
specialized perioperative care teams
Treatment sequencing is individualized through multidisciplinary evaluation and coordinated treatment planning.
Summary
Peritoneal surface malignancies represent a complex group of diseases requiring specialized expertise in tumor biology, imaging, and advanced surgical techniques.
For selected patients with disease confined to the abdominal cavity, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) offers the possibility of meaningful long-term disease control.
Modern management integrates precise staging, thoughtful systemic therapy sequencing, and complex surgical intervention within experienced multidisciplinary cancer programs.
Consultation and Referral
For Patients
Individuals seeking evaluation for peritoneal metastases or pseudomyxoma peritonei may Request a Consultation to discuss individualized treatment options.
For Referring Physicians
Physicians wishing to refer a patient or discuss complex peritoneal surface malignancies may visit For Physicians for coordinated referral pathways and multidisciplinary case discussion.